

Stephen P Ethier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9298217/publications.pdf>

Version: 2024-02-01

39
papers

4,750
citations

218592

26
h-index

315616

38
g-index

39
all docs

39
docs citations

39
times ranked

9085
citing authors

#	ARTICLE	IF	CITATIONS
1	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. <i>Cancer Cell</i> , 2006, 10, 515-527.	7.7	2,729
2	Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer. <i>Molecular Cancer Research</i> , 2005, 3, 655-667.	1.5	201
3	Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. <i>Molecular Oncology</i> , 2012, 6, 494-506.	2.1	136
4	Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. <i>Nature Communications</i> , 2016, 7, 13050.	5.8	135
5	Genomic and Expression Analysis of the 8p11-12 Amplicon in Human Breast Cancer Cell Lines. <i>Cancer Research</i> , 2004, 64, 40-47.	0.4	116
6	Reproducibility: changing the policies and culture of cell line authentication. <i>Nature Methods</i> , 2015, 12, 493-497.	9.0	114
7	Multiple Interacting Oncogenes on the 8p11-p12 Amplicon in Human Breast Cancer. <i>Cancer Research</i> , 2006, 66, 11632-11643.	0.4	109
8	MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 6641-6650.	0.4	91
9	Transforming Potential of Alternatively Spliced Variants of Fibroblast Growth Factor Receptor 2 in Human Mammary Epithelial Cells. <i>Molecular Cancer Research</i> , 2004, 2, 643-652.	1.5	89
10	Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes. <i>Experimental Cell Research</i> , 2015, 332, 223-235.	1.2	88
11	Transforming Properties of 8p11-12 Amplified Genes in Human Breast Cancer. <i>Cancer Research</i> , 2010, 70, 8487-8497.	0.4	84
12	Human breast cancer cell lines as models of growth regulation and disease progression. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1996, 1, 111-121.	1.0	64
13	Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. <i>Breast Cancer Research</i> , 2000, 2, 311-20.	2.2	62
14	Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. <i>Journal of Cellular Physiology</i> , 2007, 210, 720-731.	2.0	60
15	ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways. <i>BMC Cancer</i> , 2012, 12, 225.	1.1	55
16	SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2713-2726.	1.9	51
17	Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. <i>Molecular Cancer Research</i> , 2004, 2, 643-52.	1.5	46
18	erbB-2 Overexpression in Human Mammary Epithelial Cells Confers Growth Factor Independence*. <i>Endocrinology</i> , 1999, 140, 3615-3622.	1.4	45

#	ARTICLE	IF	CITATIONS
19	Constitutive activation of pp125fak in newly isolated human breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 1999, 54, 173-182.	1.1	45
20	Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. <i>BMC Cancer</i> , 2019, 19, 491.	1.1	42
21	Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 130.	2.2	41
22	Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ER α in SUM44 breast cancer cells and is associated with ER α overexpression in breast cancer. <i>Molecular Oncology</i> , 2016, 10, 850-865.	2.1	41
23	KAT6A, a Chromatin Modifier from the 8p11-p12 Amplicon is a Candidate Oncogene in Luminal Breast Cancer. <i>Neoplasia</i> , 2014, 16, 644-655.	2.3	37
24	Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. <i>PLoS ONE</i> , 2019, 14, e0224420.	1.1	36
25	Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines. <i>Cancer Genetics and Cytogenetics</i> , 2004, 155, 57-62.	1.0	32
26	The influence of growth factors on the proliferative potential of normal and primary breast cancer-derived human breast epithelial cells. <i>Breast Cancer Research and Treatment</i> , 1991, 17, 221-230.	1.1	30
27	The culture of cell culture practices and authentication—Results from a 2015 Survey. <i>BioTechniques</i> , 2015, 59, 189-90, 192.	0.8	25
28	Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer. <i>Advances in Cancer Research</i> , 2015, 127, 253-281.	1.9	24
29	Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer. <i>Molecular Oncology</i> , 2015, 9, 527-543.	2.1	24
30	HER-2 Signaling, Acquisition of Growth Factor Independence, and Regulation of Biological Networks Associated with Cell Transformation. <i>Cancer Research</i> , 2010, 70, 7862-7873.	0.4	19
31	Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 349-358.	1.1	19
32	erbB-2 Overexpression in Human Mammary Epithelial Cells Confers Growth Factor Independence. <i>Endocrinology</i> , 1999, 140, 3615-3622.	1.4	14
33	MYC Is a Crucial Mediator of TGF β -Induced Invasion in Basal Breast Cancer. <i>Cancer Research</i> , 2016, 76, 3520-3530.	0.4	12
34	Oridonin inhibits aberrant AKT activation in breast cancer. <i>Oncotarget</i> , 2018, 9, 23878-23889.	0.8	11
35	Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models. <i>BMC Cancer</i> , 2018, 18, 1233.	1.1	7
36	ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen. <i>Vaccine</i> , 2018, 36, 6262-6269.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. <i>Oncotarget</i> , 2016, 7, 36138-36153.	0.8	6
38	Development and implementation of the SUM breast cancer cell line functional genomics knowledge base. <i>Npj Breast Cancer</i> , 2020, 6, 30.	2.3	4
39	Estrogen Receptor Positive Breast Cancer: 8p11-p12 Amplicon and Therapeutic Response. , 2021, , .		0